Analysts Favor GT Biopharma Over Competitor Cyclo Therapeutics Market analysts project a potential upside of 378.26% for GT Biopharma, significantly outpacing Cyclo Therapeutics' 31.83%. While GT Biopharma has a stronger consensus rating, it also faces higher volatility risks. Institutional ownership remains relatively low for GT Biopharma, at 8.1%, compared to Cyclo Therapeutics' 68.6%, highlighting differing investor confidence levels.435